Zejula

• Zejula (niraparib) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor.
• It is primarily used for the maintenance treatment of advanced ovarian, fallopian tube, and primary peritoneal cancers.
• The medication works by disrupting DNA repair pathways in cancer cells, leading to their death.
• Zejula can be prescribed to patients with or without specific genetic mutations, such as BRCA.
• Common side effects include fatigue, nausea, and changes in blood cell counts, requiring regular monitoring.

What is Zejula Used to Treat?

Zejula is a prescription medication that belongs to a class of drugs known as PARP inhibitors. It is primarily indicated for the treatment of certain types of advanced cancers affecting the female reproductive system. Specifically, Zejula is used as a maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. This means it is given after initial chemotherapy has successfully reduced the cancer.

The medication’s approval extends to patients regardless of their BRCA mutation status, making it a broader option for those battling these challenging cancers. For instance, it is approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior lines of platinum-based chemotherapy and who are currently in a complete or partial response. The goal of using Zejula in these settings is to delay the recurrence of cancer, offering patients a longer period without disease progression.

How Zejula Works, Side Effects, and Drug Information

Zejula, known generically as niraparib, works in the body by inhibiting poly (ADP-ribose) polymerase (PARP) enzymes. These enzymes play a crucial role in DNA repair within cells. Cancer cells, especially those with existing DNA repair defects (like BRCA mutations), become highly dependent on PARP for survival. By blocking PARP, Zejula prevents cancer cells from repairing their damaged DNA, leading to an accumulation of genetic damage that ultimately triggers cell death. This targeted mechanism helps to selectively destroy cancer cells while minimizing harm to healthy cells, although some side effects can still occur due to the drug’s impact on rapidly dividing normal cells.

Patients taking Zejula may experience various Zejula medication side effects. It is important for individuals to discuss these with their healthcare provider, as some may require management or dose adjustments. Common side effects include:

• Fatigue or weakness
• Nausea and vomiting
• Constipation or diarrhea
• Decreased appetite
• Abdominal pain
• Changes in blood cell counts (e.g., anemia, thrombocytopenia, neutropenia)
• Headache
• Insomnia
• High blood pressure

More serious, though less common, side effects can include bone marrow disorders, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), and cardiovascular events. Regular blood tests are essential to monitor for changes in blood counts and other potential issues. In terms of Zejula drug information, it is an oral medication, typically taken once daily. Dosage may vary based on individual patient factors, including body weight and platelet count, and is often adjusted based on how well the patient tolerates the treatment. Adherence to the prescribed regimen and consistent communication with the oncology team are vital for managing treatment effectively and safely.